217 related articles for article (PubMed ID: 38223508)
1. ATF5 promotes malignant T cell survival through the PI3K/AKT/mTOR pathway in cutaneous T cell lymphoma.
Cao M; Lai P; Liu X; Liu F; Qin Y; Tu P; Wang Y
Front Immunol; 2023; 14():1282996. PubMed ID: 38223508
[TBL] [Abstract][Full Text] [Related]
2. PAK1 overexpression promotes cell proliferation in cutaneous T cell lymphoma via suppression of PUMA and p21.
Wang Y; Gu X; Li W; Zhang Q; Zhang C
J Dermatol Sci; 2018 Apr; 90(1):60-67. PubMed ID: 29307600
[TBL] [Abstract][Full Text] [Related]
3. Cutaneous T cell lymphoma: the helping hand of dendritic cells.
Edelson RL
Ann N Y Acad Sci; 2001 Sep; 941():1-11. PubMed ID: 11594563
[TBL] [Abstract][Full Text] [Related]
4. Aberrant CD137 ligand expression induced by GATA6 overexpression promotes tumor progression in cutaneous T-cell lymphoma.
Kamijo H; Miyagaki T; Shishido-Takahashi N; Nakajima R; Oka T; Suga H; Sugaya M; Sato S
Blood; 2018 Nov; 132(18):1922-1935. PubMed ID: 30194255
[TBL] [Abstract][Full Text] [Related]
5. LW-213 induces cell apoptosis in human cutaneous T-cell lymphomas by activating PERK-eIF2α-ATF4-CHOP axis.
Yu XX; Zhu MY; Wang JR; Li H; Hu P; Qing YJ; Wang XY; Wang HZ; Wang ZY; Xu JY; Guo QL; Hui H
Acta Pharmacol Sin; 2021 Feb; 42(2):290-300. PubMed ID: 32747719
[TBL] [Abstract][Full Text] [Related]
6. Molecular profiling of TOX-deficient neoplastic cells in cutaneous T cell lymphoma.
Xu J; Huang H; Wang S; Chen Y; Yin X; Zhang X; Zhang Y
Arch Dermatol Res; 2020 Sep; 312(7):513-525. PubMed ID: 31676945
[TBL] [Abstract][Full Text] [Related]
7. A genome-wide RNA interference screen reveals an essential CREB3L2-ATF5-MCL1 survival pathway in malignant glioma with therapeutic implications.
Sheng Z; Li L; Zhu LJ; Smith TW; Demers A; Ross AH; Moser RP; Green MR
Nat Med; 2010 Jun; 16(6):671-7. PubMed ID: 20495567
[TBL] [Abstract][Full Text] [Related]
8. Simultaneous inhibition of mTOR-containing complex 1 (mTORC1) and MNK induces apoptosis of cutaneous T-cell lymphoma (CTCL) cells.
Marzec M; Liu X; Wysocka M; Rook AH; Odum N; Wasik MA
PLoS One; 2011; 6(9):e24849. PubMed ID: 21949767
[TBL] [Abstract][Full Text] [Related]
9. Polo-like kinase 1 (Plk1) is expressed by cutaneous T-cell lymphomas (CTCLs), and its downregulation promotes cell cycle arrest and apoptosis.
Nihal M; Stutz N; Schmit T; Ahmad N; Wood GS
Cell Cycle; 2011 Apr; 10(8):1303-11. PubMed ID: 21436619
[TBL] [Abstract][Full Text] [Related]
10. Proapoptotic and antiapoptotic markers in cutaneous T-cell lymphoma skin infiltrates and lymphomatoid papulosis.
Nevala H; Karenko L; Vakeva L; Ranki A
Br J Dermatol; 2001 Dec; 145(6):928-37. PubMed ID: 11899146
[TBL] [Abstract][Full Text] [Related]
11. Understanding Cell Lines, Patient-Derived Xenograft and Genetically Engineered Mouse Models Used to Study Cutaneous T-Cell Lymphoma.
Gill RPK; Gantchev J; Martínez Villarreal A; Ramchatesingh B; Netchiporouk E; Akilov OE; Ødum N; Gniadecki R; Koralov SB; Litvinov IV
Cells; 2022 Feb; 11(4):. PubMed ID: 35203244
[TBL] [Abstract][Full Text] [Related]
12. Recurrent mutations in epigenetic modifiers and the PI3K/AKT/mTOR pathway in subcutaneous panniculitis-like T-cell lymphoma.
Li Z; Lu L; Zhou Z; Xue W; Wang Y; Jin M; Qiu Y; Sun W; Fu X; Zhang X; Chang Y; Nan F; Yan J; Wang G; Sun Z; Fu X; Li L; Li X; Wang X; Wu J; Zhang L; Zhang M
Br J Haematol; 2018 May; 181(3):406-410. PubMed ID: 28294301
[No Abstract] [Full Text] [Related]
13. Thrombospondin-1 promotes tumor progression in cutaneous T-cell lymphoma via CD47.
Kamijo H; Miyagaki T; Takahashi-Shishido N; Nakajima R; Oka T; Suga H; Sugaya M; Sato S
Leukemia; 2020 Mar; 34(3):845-856. PubMed ID: 31712778
[TBL] [Abstract][Full Text] [Related]
14. FOXK1 promotes malignant progression of breast cancer by activating PI3K/AKT/mTOR signaling pathway.
Li ZQ; Qu M; Wan HX; Wang H; Deng Q; Zhang Y
Eur Rev Med Pharmacol Sci; 2019 Nov; 23(22):9978-9987. PubMed ID: 31799667
[TBL] [Abstract][Full Text] [Related]
15. Single-Cell Lymphocyte Heterogeneity in Advanced Cutaneous T-cell Lymphoma Skin Tumors.
Gaydosik AM; Tabib T; Geskin LJ; Bayan CA; Conway JF; Lafyatis R; Fuschiotti P
Clin Cancer Res; 2019 Jul; 25(14):4443-4454. PubMed ID: 31010835
[TBL] [Abstract][Full Text] [Related]
16. Insights Into the Molecular and Cellular Underpinnings of Cutaneous T Cell Lymphoma.
Yumeen S; Girardi M
Yale J Biol Med; 2020 Mar; 93(1):111-121. PubMed ID: 32226341
[TBL] [Abstract][Full Text] [Related]
17. In vitro evaluation of Neosetophomone B inducing apoptosis in cutaneous T cell lymphoma by targeting the FOXM1 signaling pathway.
Kuttikrishnan S; Masoodi T; Ahmad F; Sher G; Prabhu KS; Mateo JM; Buddenkotte J; El-Elimat T; Oberlies NH; Pearce CJ; Bhat AA; Alali FQ; Steinhoff M; Uddin S
J Dermatol Sci; 2023 Nov; 112(2):83-91. PubMed ID: 37865581
[TBL] [Abstract][Full Text] [Related]
18. Preclinical Evidence for Targeting PI3K/mTOR Signaling with Dual-Inhibitors as a Therapeutic Strategy against Cutaneous T-Cell Lymphoma.
Bresin A; Cristofoletti C; Caprini E; Cantonetti M; Monopoli A; Russo G; Narducci MG
J Invest Dermatol; 2020 May; 140(5):1045-1053.e6. PubMed ID: 31682844
[TBL] [Abstract][Full Text] [Related]
19. IL-2- and IL-15-induced activation of the rapamycin-sensitive mTORC1 pathway in malignant CD4+ T lymphocytes.
Marzec M; Liu X; Kasprzycka M; Witkiewicz A; Raghunath PN; El-Salem M; Robertson E; Odum N; Wasik MA
Blood; 2008 Feb; 111(4):2181-9. PubMed ID: 18025151
[TBL] [Abstract][Full Text] [Related]
20. Diminished microRNA-29b level is associated with BRD4-mediated activation of oncogenes in cutaneous T-cell lymphoma.
Kohnken R; Wen J; Mundy-Bosse B; McConnell K; Keiter A; Grinshpun L; Hartlage A; Yano M; McNeil B; Chakravarti N; William B; Bradner JE; Caligiuri MA; Porcu P; Mishra A
Blood; 2018 Feb; 131(7):771-781. PubMed ID: 29180399
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]